Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06267729 · ClinicalTrials.gov registry record · Phase 1

Study of AZD0754 in Participants With Metastatic Prostate Cancer

A Phase 1 study of Metastatic Prostate Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
15
Study locations

NCT06267729: Recruiting Phase 1 study of Metastatic Prostate Cancer, sponsored by AstraZeneca.

NCT06267729 is a Phase 1 study of Metastatic Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 60 participants, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (68% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06267729, a Phase 1 study of Metastatic Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

Primary Outcome

Determine if treatment with AZD0754 is safe and tolerable through assessment of DLTs/DLT-like events, AEs, AESIs, SAEs, and changes from baseline in laboratory parameters, vital signs, and ECGs.

Conditions Studied

Metastatic Prostate Cancer

Interventions

  • BIOLOGICAL AZD0754
  • BIOLOGICAL AZD2287

Study Locations (15)

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

New York

  • Research Site - New York
  • Research Site - New York

Texas

  • Research Site - Dallas
  • Research Site - Houston

Other

  • Research Site - East Melbourne
  • Research Site - Pamplona

California

  • Research Site - Duarte

Florida

  • Research Site - Tampa

Georgia

  • Research Site - Atlanta

Kansas

  • Research Site - Westwood

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-03-12
Est. Completion 2026-11-24
Phase Phase 1
AstraZeneca

1,285 total trials

What NCT06267729 shows while recruiting

NCT06267729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 185-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (68% lower).

The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which AZD0754 is the first listed.

NCT06267729 lists 15 locations in 11 states (Massachusetts, New York, Texas).

Frequently Asked Questions

What is clinical trial NCT06267729 about?

NCT06267729 is a clinical study titled "Study of AZD0754 in Participants With Metastatic Prostate Cancer". The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

What is the current status of trial NCT06267729?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-03-12. Estimated completion is 2026-11-24.

What conditions does trial NCT06267729 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer.

What interventions are being tested in trial NCT06267729?

The interventions under investigation include: AZD0754 (BIOLOGICAL), AZD2287 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06267729?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06267729 being conducted?

This trial has 15 study locations across California, Florida, Georgia, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06267729's enrollment target sits among peer trials

60 22nd of 41 higher than 20 of 41 other Metastatic Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06267729

Source: ClinicalTrials.gov NCT06267729, the US trial registry maintained by the National Library of Medicine. NCT06267729 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.